Sign in
Active, not recruitingNo phase

Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea

Key facts

Who runs it
Cryosa, Inc.
Where
Albany, Aurora, Bethlehem, Chicago, Houston, Memphis, Miami, New Orleans, and Philadelphia, United StatesSee the 9 sites
Trial code
Status
Active, not recruiting
People taking part
25 people, planned
Started
12 Sept 2023
Expected to end
30 Jul 2028
Type of study
Interventional
Treatments tested
  • Cryosa Procedure
Record updated
11 August 2026

Who can take part

Age
22 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 42 criteriaShow less

Who can take part

  • To participate in this study, the subject must meet ALL of the following inclusion criteria:
  • Age 22 - 70 years
  • Not able to use, refuse to use or intolerant of Positive Airway Pressure (PAP) or Mandibular Advancement Device (MAD) if using, must be < 4 hours per night, < 5 days/week
  • Failed, are not candidates for, or have refused other invasive procedures such as hypoglossal nerve stimulation or pharmacotherapy for the primary treatment of OSA such as Tirzepatide
  • BMI ≥30 or ≤ 40 kg/m2 at enrollment
  • AHI ≥30 at enrollment based on in-lab polysomnography study OR AHI ≥ 15 and BMI of ≥ 30 at enrollment based on in-lab polysomnography study Is geographically stable and in close proximity to the site
  • Able and willing to provide written consent to participate in the study

Who cannot take part

  • Actively undergoing immunotherapy (Allergy shots)*, or unwilling to washout of allergy shots at least 2 weeks prior to study procedure; Patients receiving immunotherapy may be eligible if they undergo a 2-week wash-out prior to the study procedure
  • Previous surgery within 12 weeks of scheduled procedure performed on the soft tissue of the upper airway (e.g., uvula, soft palate, or tonsils)
  • Prior sleep surgeries, including tongue base reduction, UPPP and hypoglossal nerve stimulation
  • Resistant hypertension defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses
  • Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (< 12 months) myocardial infarction or severe cardiac arrhythmias
  • Patients taking any of the following medication that could affect study endpoints: benzodiazepines, Z-drugs (zolpidem and eszopiclone) opiates, antipsychotics (neuroleptics), phenothiazines, and prescription stimulants (including Sunosi, Provigil, and Nuvigil)
  • Severe maxillary mandibular insufficiency that in the opinion of the investigator thought to be the primary cause of OSA
  • Oral cancer or non-healing oral wounds
  • History of radiation therapy to neck or upper respiratory tract
  • Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat (with exception of tonsillectomy and/or adenoidectomy)
  • History presence of cold urticaria at the time of screening History of cryoglobulinemia
  • History of allergy to glycerin
  • History of hospitalization with mechanical ventilation due to COVID-19 per investigator discretion
  • Patients with diagnosed autoimmune disorders including thyroid disease, lupus, multiple myeloma, chronic lymphocytic leukemia
  • Neuromuscular disease or other neurologic deficits (for example multiple sclerosis, muscular dystrophy, Parkinson's disease, transient ischemic attack, epilepsy or cerebrovascular accident)
  • Diagnosis of any moderate to severe congestive obstructive pulmonary disease (COPD)
  • Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism) History of angioedema of the airway
  • Hereditary angioedema and other autoimmune disorders that could lead to acquired angioedema - confirmed with a compliment component C4 blood test <13mg/dL
  • Subjects with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months
  • Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months
  • History or current clinical evidence of TIA or stroke or muscular dysfunction
  • Known active substance use disorder
  • Other severe sleep disorders that in the opinion of the investigator, confound functional assessments of sleepiness such as narcolepsy with cataplexy, severe insomnia/insomnia secondary to chronic pain, PTSD
  • Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject's ability to meet study requirements and ability to provide study consent
  • Uncontrolled Diabetes (including Diabetes Mellitus [DM] or Insulin Dependent Diabetes Mellitus [IDDM]) with HbA1c >9
  • Females who are pregnant or females of childbearing age with intention to become pregnant during the study period (≤ 3 months from treatment date)
  • Contraindication to general anesthesia or in the opinion of the Investigator would not be able to tolerate the procedure, including intubation during the procedure or in response to an adverse event
  • Actively taking ACEs/ARBs
  • Severe uncontrolled asthma
  • Obvious severe fixed upper airway obstructions (tumors, polyps, nasal obstruction)
  • Current smoker (≥ 1 pack/day)
  • Presence of occupational shift work or anticipation of shift changes during the next 2 years
  • Subject has sleep hygiene behavior that is likely to interfere with measurement outcomes during PSG and/or HSAT
  • Any other reason the investigator deems subject is unfit for participation in the study
  • Subject currently participating in other premarket investigational studies unless approved by Sponsor in writing

Where in United States

  • Albany ENT & Allergy ServicesAlbany, United States
  • UCHealth University of ColoradoAurora, United States
  • Specialty Physician AssociatesBethlehem, United States
  • Rush University Medical CenterChicago, United States
  • Houston Methodist HospitalHouston, United States
  • University of Tennessee Health Sciences CenterMemphis, United States
  • University of MiamiMiami, United States
  • Ochsner Baptist Medical CenterNew Orleans, United States
  • University of PennsylvaniaPhiladelphia, United States

About the trial

What the trial wants to find out

This is a prospective, multicenter, non-randomized single-arm safety and performance study to collect data to evaluate the safety of the Cryosa procedure to treat obstructive sleep apnea (OSA) in patients with moderate to severe OSA. The study will also evaluate the chronic performance of the Cryosa system and collect clinical measures for therapy effectiveness that will be used to demonstrate safety and effectiveness in the next clinical study.

The group in the trial

  • Cryosa ProcedureTreatment being tested

    The purpose of this study is to evaluate the safety and effectiveness of Cryosa System applied to the tongue and soft palate in patients with clinically diagnosed obstructive sleep apnea (OSA).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicenter Pilot Study of the Cryosa System for the Treatment of Obstructive Sleep Apnea
Record updated
11 August 2026